CRISPR Technology Market by Offering (Product, Services), Application (Agricultural, Biomedical, Industrial), End User - Global Forecast 2024-2030
Description
CRISPR Technology Market by Offering (Product, Services), Application (Agricultural, Biomedical, Industrial), End User - Global Forecast 2024-2030
The CRISPR Technology Market size was estimated at USD 3.25 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 16.52% to reach USD 9.49 billion by 2030.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a highly precise and efficient genome-editing tool derived from a bacterial defense mechanism, which allows for targeted manipulation of the DNA sequence within an organism's genome. This innovative biotechnology tool enables precise genome editing through RNA-guided Cas9 nucleases, facilitating targeted genetic modifications across healthcare, agriculture, and bioenergy industries. Increased funding for research activities, advancements in gene therapy, the growing prevalence of genetic disorders, and the need for more efficient crop production methods increase the use of CRISPR technology. However, ethical concerns surrounding gene editing, especially in human germline cells, and regulatory hurdles in different regions may impede the adoption or commercialization of CRISPR products. Nevertheless, creating new genetically modified crops (GMO) with enhanced nutritional value or resistance to pests and diseases and advancing drug discovery by screening large libraries of compounds against specific targets using CRISPR systems creates lucrative opportunities for the CRISPR technology market.
Regional Insights
In America, the CRISPR technology market represents significant growth due to extensive research and development activities, substantial investments by both public and private sectors, and advances in bioinformatics. In addition, robust and steadily growing sectors such as agriculture, biotechnology, drug discovery, and therapeutics increased demand for CRISPR technology. The APAC region boasts increasing biopharmaceutical industries investing heavily in gene-editing technologies for agricultural advancements and disease treatment applications. Additionally, factors such as government support for genomics research and strategic collaborations with international organizations have accelerated market growth in this region. Europe has experienced considerable growth due to its well-established pharmaceutical infrastructure and funding from various organizations for genome editing research projects. Moreover, the Middle-East and Africa sub-segments focus on therapeutic applications of CRISPR for diseases such as sickle cell anemia and beta-thalassemia.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the CRISPR Technology Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Growing need for new vaccines and treatments for genetic diseases
- Increasing private and public investments in biotechnological and pharmaceutical sectors
- Market Restraints
- High cost and complexities involved in the government regulations
- Market Opportunities
- Advancements and improvements in CRISPR technology
- Potential use of CRISPR technology in the agriculture sector
- Market Challenges
- Technical challenges and ethical concerns associated with CRISPR technology
- Market Segmentation Analysis
- Offering: Increasing use of CRISPR kits & reagents with the surging research activities and product improvements
- Application: Proliferating use of CRISPR technology in the agricultural sector
- End-User: Potential application of CRISPR technology in biotechnology companies
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CRISPR Technology Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CRISPR Technology Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- RoslinCT Manufacture CRISPR-Based Therapy
RoslinCT announced its role in producing the revolutionary CRISPR-based gene-editing therapy, exa-cel, under the brand name Casgevy. This milestone therapy, created to combat sickle cell disease and transfusion-dependent beta-thalassemia, has received approval from the U.K.
First Human CRISPR Drug Moves Forward
Vertex Pharmaceuticals and CRISPR Therapeutics' collaborative innovation, exa-cel, received critical endorsement from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee. This CRISPR-based therapy, which heralds a new frontier in medicine, stands on the verge of FDA approval, promising significant respite for sickle cell patients.
ERS Genomics Limited (‘ERS’) Completes Licensing Agreement With Syngene International
ERS Genomics Limited has solidified a licensing arrangement with Syngene International, India's contract research organization. The agreement grants Syngene access to the essential CRISPR/Cas9 intellectual property, promising to enhance technical innovation within India and benefit its international clientele. This strategic move amplifies India's stature in the global biotech and life sciences arena. At the same time, both firms aim to propel scientific evolution and translate groundbreaking research into practical applications.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CRISPR Technology Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the CRISPR Technology Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Applied StemCell, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., ERS Genomics Limited, Function Oncology, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Scribe Therapeutics, Sherlock Biosciences, Inc., Synthego Corporation, Takara Holdings Inc., Thermo Fisher Scientific Inc., ToolGen, Inc., TriLink BioTechnologies by Maravai Intermediate Holdings, LLC, Twist Bioscience Corporation, and Verve Therapeutics, Inc..
Market Segmentation & Coverage
This research report categorizes the CRISPR Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:- Offering
- Product
- Enzymes
- Guide RNA
- Kits & Reagents
- Services
- Cell Line Engineering
- gRNA Design & Vector Construction
- Screening Services
- Application
- Agricultural
- Biomedical
- Industrial
- End User
- Academics & Government Research Institutes
- Biotechnology Companies
- Agricultural Companies
- Pharmaceutical Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Georgia
- Illinois
- Kentucky
- Michigan
- Mississippi
- New Jersey
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Product
- Market Drivers
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing need for new vaccines and treatments for genetic diseases
- 5.1.1.2. Increasing private and public investments in biotechnological and pharmaceutical sectors
- 5.1.2. Restraints
- 5.1.2.1. High cost and complexities involved in the government regulations
- 5.1.3. Opportunities
- 5.1.3.1. Advancements and improvements in CRISPR technology
- 5.1.3.2. Potential use of CRISPR technology in the agriculture sector
- 5.1.4. Challenges
- 5.1.4.1. Technical challenges and ethical concerns associated with CRISPR technology
- 5.2. Market Segmentation Analysis
- 5.2.1. Offering: Increasing use of CRISPR kits & reagents with the surging research activities and product improvements
- 5.2.2. Application: Proliferating use of CRISPR technology in the agricultural sector
- 5.2.3. End-User: Potential application of CRISPR technology in biotechnology companies
- 5.3. Market Trend Analysis
- 5.3.1. Increasing research and development by key players and growing application of CRISPR technology in agriculture in the Americas
- 5.3.2. Ongoing research and strategic collaborations for higher agricultural productivity using CRISPR technologies coupled with adoption of CRISPR in point-of-care testing in the APAC region
- 5.3.3. Increasing approvals for the usage of CRISPR technology for disease management coupled with growing research activities in the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 5.8. Client Customization
- 5.8.1. CRISPR becoming a viable solution for bioenergy production
- 5.8.2. Expanding patent landscape for CRISPR technology
- 6. CRISPR Technology Market, by Offering
- 6.1. Introduction
- 6.2. Product
- 6.3. Services
- 7. CRISPR Technology Market, by Application
- 7.1. Introduction
- 7.2. Agricultural
- 7.3. Biomedical
- 7.4. Industrial
- 8. CRISPR Technology Market, by End User
- 8.1. Introduction
- 8.2. Academics & Government Research Institutes
- 8.3. Biotechnology Companies
- 9. Americas CRISPR Technology Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific CRISPR Technology Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa CRISPR Technology Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.3.1. RoslinCT Manufacture CRISPR-Based Therapy
- 12.3.2. First Human CRISPR Drug Moves Forward
- 12.3.3. ERS Genomics Limited (‘ERS’) Completes Licensing Agreement With Syngene International
- 12.3.4. Revvity's (RVTY) New Launch to Widen Access to Editing Technology
- 12.3.5. Pencil Biosciences Raises GBP 5.6 Million to Advance Gene Editing for Rare Diseases
- 12.3.6. Integrated DNA Technologies and Aldevron Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers
- 12.3.7. Bedoukian Research Inc. Partners with Inscripta to Sustainably Develop and Manufacture Naturally Produced Ingredients
- 12.3.8. Scribe Announces Collaboration to Accelerate In Vivo CRISPR-Based Genetic Medicines
- 12.3.9. Vertex Teases Launch Plans for First Crispr Gene Editing Therapy Ahead of FDA Decision
- 12.3.10. Sherlock Biosciences to Acquire Sense Biodetection
- 12.3.11. Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
